2024年5月20日 · Multidrug-resistant TB (MDR-TB) is a form of TB disease caused by a strain of M. tuberculosis complex that is resistant to rifampicin and isoniazid. Globally, an estimated …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment - Drug-Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member States on …

TB strains may be susceptible or resistant to isoniazid (i.e. MDR-TB), or resistant to other first-line TB medicines (polyresistant) or second-line TB medicines (e.g. extensively drug-resistant …

Estimated levels of treatment coverage for MDR/RR-TB in 2022, approximated as the number of people enrolled on treatment for MDR-TB in 2022 divided by the estimated number of people …

Commonly used terms and key definitions in DR-TB treatment. 3. Key considerations in DR-TB treatment. 4. The 6-month bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) …

About 410,000 new cases of multidrug-resistant1 or rifampicin-resistant tuberculosis (MDR/RR-TB) were estimated to occur in 2022. While all of these would have been eligible for a second …

In multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens, all three Group A agents and at least one Group B agent should be included to ensure that …

This current module on DR-TB treatment provides specific recommendations on the treatment of DR-TB, including use of regimens for rifampicin-susceptible, isoniazid-resistant TB (Hr-TB), all …

Most attention has been given to the proportion of people diagnosed with TB who have rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB, defined as resistance to both …

The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB and multidrug- and rifampicin-resistant , including longer and shorter regimens for …